eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img

Risk minimisation materials

The ELIQUIS® (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications, aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk.

More information on each of these documents can be found
at www.medicines.org.uk/emc/product/2878/rmms (5 mg)

or www.medicines.org.uk/emc/product/4756/rmms (2.5 mg).

Diagnosemethoden

Full prescribing information is in the ELIQUIS SmPC

Download guides designed for your patients


Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   
DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
SmPC = Summary of Product Characteristics

* ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor indicated for:

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (New York Heart Association Class ≥II)1
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.